Sign in Create account

Aurobindo Pharma Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: AUROPHARMA BSE: 524804
₹1672.00
▼ -25.70 (-1.51%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
83/100
Strong
Valuation
54/100
Fairly Valued
Momentum
50/100
Neutral

QVM read Quality business Quality Strong, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

About

Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company based in HITEC City, Hyderabad, with U.S. headquarters in East Windsor, Mercer County, New Jersey. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include Pfizer and AstraZeneca.

Source: Wikipedia

Key Metrics

Market Capitalization
₹96,203 Cr
PE (TTM)
37.4
Industry median 36.1 (152 companies)
Price to Book
2.5
PEG (TTM)
1.2
Institutions holding %
41.48%
FII + DII, latest filed period
Piotroski Score
8
Relative return vs Nifty50, qtr %
16.6
Relative return vs Sector, qtr %
7.7
Free Cash Flow
₹2,841 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
32.40%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
31.16%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-1.75%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
31.85%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-1.71%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.81
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.20
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
18.09
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
26.33%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
37.69%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
32.56%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
5.99%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
13.58%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
9.25%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

5 of 8 met
  • Yes Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • Yes Piotroski F-score is 7 or more (score 8)
  • Yes Debt to equity is below 0.5 (0.20)
  • No Return on equity is 15% or more (9.2%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • No Promoter pledge is 5% of their holding or less and not rising (13.8% pledged)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

1 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Fair Value Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.5%
Low 1649.3000 · High 1707.2000
1W return
-2.9%
Low 1649.3000 · High 1740.0000
1M return
-2.6%
Low 1622.6000 · High 1740.0000
52W return
54.0%
Low 1066.8000 · High 1740.0000
Lifetime High ₹1734.0000 (Sept. 18, 2026)
Lifetime Low ₹47.4500 (Sept. 24, 1996)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish3
Bearish3
5D
1692.9
10D
1694.7
20D
1684.5
50D
1642.6
100D
1567.1
200D
1412.3

Delivery and volume

Day avg. delivery
50.0%
Week avg. delivery
55.4%
Month avg. delivery
50.6%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1676.17
Pivot
First resistance1703.03
Second resistance1734.07
Third resistance1760.93
First support1645.13
Second support1618.27
Third support1587.23
Day RSI49.3
Day MFI51.5
Day MACD16.71
Day MACD signal20.64

Beta

1M0.52
3M0.21
1Y0.37
3Y0.65

Price change analysis

↓ -2.6%
Over 1 Month
LowHigh
1622.601740.00
↑ 7.7%
Over 3 Months
LowHigh
1512.001740.00
↑ 24.6%
Over 6 Months
LowHigh
1266.101740.00
↑ 54.0%
Over 1 Year
LowHigh
1066.801740.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 37.4 (own history: 31.1–41.3)
Fair Value Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹2,800 Cr
Net profit (June 30, 2026)
₹737 Cr
Basic EPS (June 30, 2026)
₹12.7500

Ranks #9 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter51.88%
  • Mutual funds16.71%
  • FII/FPI16.38%
  • Other DII8.39%
  • Public6.64%

Largest holders

NameCategoryShares %Shares
RPR SONS ADVISORS PRIVATE LIMITED, MRS.P.SUNEELA RANI (JOINTLY HOLDING)Promoter33.5400%192997923
QUANT MUTUAL FUNDPublic4.9600%28547559
KAMBAM NITHYANANDA REDDYPromoter4.3700%25148052
KIRTHI REDDY KAMBAMPromoter3.4600%19901635
HDFC MUTUAL FUNDPublic3.2200%18529213

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings increased from 51.82% to 51.88% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 15.24% to 16.38% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 17.79% to 16.71% in Jun 2026 qtr

64 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 498 insider trades, 27 SAST, 299 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
1 Apr 2024 RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) Promoter group Pledge Revoke 0 ₹1,266.85 Cr
28 Mar 2024 RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) Promoter group Pledge 0 ₹1,758.59 Cr
5 Mar 2024 PAVANKUMAR PS Employee / designated person Sell 0 ₹0
1 Mar 2024 CHANDRASEKHAR REDDY KANDATI Employee / designated person Sell 0 ₹0
26 Feb 2024 RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) Promoter group Pledge Revoke 0 ₹1,049.02 Cr
26 Feb 2024 RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) Promoter group Pledge Revoke 0 ₹240.07 Cr
23 Feb 2024 PAVANKUMAR PS Employee / designated person Sell 0 ₹0
21 Feb 2024 K NAGARAJU Other Sell 0 ₹0
21 Feb 2024 Dr AMBATI RAMA MOHANA RAO Employee / designated person Sell 0 ₹0
16 Feb 2024 RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) Promoter group Pledge 0 ₹1,334.77 Cr

All insider and SAST disclosures →

Deals (Bulk & Block)

All 102 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
16 Oct 2025 GOLDMAN SACHS BANK EUROPESE - ODI Block Buy 106,228 1107.0000 NSE
16 Oct 2025 GOLDMAN SACHS (SINGAPORE) PTE.- ODI Block Sell 106,228 1107.0000 NSE
25 Jan 2024 SOCIETE GENERALE Block Sell 107,558 1160.1000 NSE
25 Jan 2024 MARSHALL WACE INVESTMENT STRATEGIES TOPS FUND Block Buy 44,921 1160.1000 NSE
25 Jan 2024 MARSHALL WACE INVESTMENT STRATEGIES MARKET NEUTRAL TOPS FUND Block Buy 8,134 1160.1000 NSE
25 Jan 2024 MARSHALL WACE INVESTMENT STRATEGIES SYSTEMATIC ALPHA PLUS FUND Block Buy 862 1160.1000 NSE
25 Jan 2024 MARSHALL WACE INVESTMENT STRATEGIES EUREKA FUND Block Buy 53,641 1160.1000 NSE
25 Jan 2024 MARSHALL WACE INVESTMENT STRATEGIES - SYSTEMATIC ALPHA PLUS FUND Block Buy 15,950 1160.1000 BSE
25 Jan 2024 MARSHALL WACE INVESTMENT STRATEGIESGTOPS FUND Block Buy 27,571 1160.1000 BSE
25 Jan 2024 MARSHALL WACE INVESTMENT STRATEGIES - EUREKA FUND Block Buy 106,480 1160.1000 BSE

All bulk and block deals →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
5 Aug 2026 Financial Results Yes
21 May 2026 Financial Results Yes
6 Apr 2026 Buyback —
9 Feb 2026 Financial Results Yes
5 Nov 2025 Financial Results Yes

Corporate Announcements

All 16 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
3 Oct 2026 Company Update Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
2 Oct 2026 Company Update Aurobindo Pharma Ltd - 524804 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
2 Oct 2026 Company Update Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Acquisition
1 Oct 2026 Company Update Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Acquisition
30 Sep 2026 Company Update Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
29 Sep 2026 Company Update Aurobindo Pharma Ltd - 524804 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
21 Sep 2026 Company Update Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
15 Sep 2026 Company Update Aurobindo Pharma Ltd - 524804 - Completion Of US FDA Inspection At Unit-II Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company
15 Sep 2026 Company Update Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
12 Sep 2026 Company Update Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Acquisition

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong net profit margin (26.3%)
  • Low financial leverage (Debt/Equity 0.20)
  • Comfortable interest coverage (18.1x)
  • Healthy liquidity (Current Ratio 1.81)

Weaknesses

  • Low Return on Equity (9.2%)
  • Declining revenue YoY (-1.7%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (37.4) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Single-stock futures and a real listed options chain available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.

Part of: NIFTY 200, NIFTY 200, NIFTY 500, NIFTY 500, NIFTY MIDCAP 100, NIFTY MIDCAP 100, NIFTY MIDCAP 150, NIFTY MIDCAP 150, NIFTY MIDCAP 50, NIFTY MIDCAP 50, NIFTY PHARMA, NIFTY PHARMA

Frequently asked questions about Aurobindo Pharma Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.